# EU-1-13-830_public-assessment-report_20130613_20130613_stribild-epar-public-assessment-report.pdf

EUROPEAN MEDICINES AGENCY
SCIENCE
MEDICINES
HEALTH
21 March 2013
EMA/332263/2013
Committee for Medicinal Products for Human Use (CHMP)
Assessment report
Stribild
International non-proprietary name: ELVITEGRAVIR / cobicistat /
EMTRICITABINE / TENOFOVIR DISOPROXIL
Procedure No. EMEA/H/C/002574/0000
Note
Assessment report as adopted by the CHMP with all information of a commercially confidential nature
deleted.
7 Westferry Circus . Canary Wharf . London E14 4HB . United Kingdom
Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8416
E-mail info@ema.europa.eu Website www.ema.europa.eu
An agency of the European Union
European Medicines Agency, 2013. Reproduction is authorised provided the source is acknowledged.
Table of contents
1. Background information on the procedure
7
7
1.1. Submission of the dossier
1.2. Steps taken for the assessment of the product.
8
2. Scientific discussion
9
2.1. Introduction.
9
2.1.1. Problem statement
9
2.1.1. About the product
10
2.2. Quality aspects
11
2.2.1. Introduction
11
2.2.2. Active Substance
11
2.2.3. Finished Medicinal Product
18
2.2.4. Discussion on chemical, pharmaceutical and biological aspects
20
2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects
20
2.2.6. Recommendation(s) for future quality development
20
2.3. Non-clinical aspects
20
2.3.1. Introduction
20
2.3.2. Pharmacology
21
2.3.3. Pharmacokinetics
22
2.3.4. Toxicology
23
2.3.5. Ecotoxicity/environmental risk assessment
25
2.3.6. Discussion on non-clinical aspects.
29
2.3.7. Conclusion on the non-clinical aspects.
31
2.4. Clinical aspects
32
2.4.1. Introduction
32
2.4.2. Pharmacokinetics.
32
2.4.3. Pharmacodynamics
65
2.4.4. Discussion on clinical pharmacology
78
2.4.5. Conclusions on clinical pharmacology
79
2.5. Clinical efficacy
79
2.5.1. Dose response studies
80
2.5.2. Main studies
81
2.5.3. Discussion on clinical efficacy
99
2.5.4. Conclusions on the clinical efficacy
100
2.6. Clinical safety
101
2.6.1. Discussion on clinical safety
119
2.6.2. Conclusions on the clinical safety
121
2.7. Pharmacovigilance.
122
2.8. User consultation
143
3. Benefit-Risk Balance.
143
4. Recommendations
144
Assessment report
EMA/332263/2013
Page 2/147
